SCHEMBL2209133

SCHEMBL2209133

COc1cccc2oc(C(=O)C3CCC(N)CC3)nc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
HSD17B10 Q99714 2/20 0.38
TSHR P16473 1/20 0.38
HCRTR1 O43613 5/20 0.37
HCRTR2 O43614 4/20 0.37
HTR3A P46098 2/20 0.36
KCNH2 Q12809 2/20 0.36
KDM4E B2RXH2 2/20 0.36
HPGD P15428 2/20 0.36
CYP3A4 P08684 1/20 0.36
MEN1 O00255 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
EDNRA P25101 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2209138 1.00 ALDH1A1 (0.38) ALDH1A1MAPTHSD17B10TSHRHCRTR1
SCHEMBL2203600 0.80 KDM1A (0.40) HTR3AKCNH2CYP3A4
SCHEMBL2203596 0.80 KDM1A (0.40) HTR3AKCNH2CYP3A4
SCHEMBL6958263 0.76 LMNA (0.47) ALDH1A1MAPTHSD17B10TSHRKDM4E
SCHEMBL5036483 0.67 MCHR1 (0.50) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL6823880 0.67 CA12 (0.57) MAPTHPGDKMT2ANPC1RAB9A
SCHEMBL6955824 0.66 ALDH1A1 (0.43) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL20931281 0.65 ELANE (0.49) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL9768577 0.65 NQO2 (0.46) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL5040838 0.65 NPC1 (0.44) ALDH1A1MAPTHCRTR1HCRTR2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981886-B2 Antibiotics derivatives ACTELION PHARMACEUTICAL LTD. (CH) 2011-07-19 US disclosed
EP-1888574-B1 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-09-02 EP disclosed
US-20080280888-A1 Antibiotics Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-11-13 US disclosed
EP-1888574-A2 NEW ANTIBIOTIC DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2008-02-20 EP disclosed
WO-2006126171-A2 NEW ANTIBIOTIC DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280888-A1 Antibiotics Derivatives NR4A1, NR2C2, NR4A3 ALDH1A1 3969/4885MAPT 4688/4885HSD17B10 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.